Published in Neuromolecular Med on June 10, 2008
Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry (2012) 1.47
Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma. J Alzheimers Dis (2010) 0.94
Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener (2010) 0.94
Biomarkers in Alzheimer's disease: past, present and future. Biomark Med (2010) 0.93
Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study. Exp Gerontol (2009) 0.88
BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis (2011) 0.87
Vitamin D2-enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPswe/PS1dE9 transgenic mice. PLoS One (2013) 0.78
Heparan sulfate proteoglycans mediate Aβ-induced oxidative stress and hypercontractility in cultured vascular smooth muscle cells. Mol Neurodegener (2016) 0.75
Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker. Alzheimers Dement (Amst) (2015) 0.75
Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4⁺ T cells 10-20 years before men. Transl Psychiatry (2014) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care (1998) 18.69
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 8.31
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 4.77
Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron (2003) 4.70
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA (2003) 4.16
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Alzheimer's disease: genotypes, phenotypes, and treatments. Science (1997) 3.72
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
"Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology (2000) 3.57
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci (2001) 3.35
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem (1989) 3.26
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci (2005) 3.23
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem (1996) 3.10
Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci (1998) 3.03
Clearing the brain's amyloid cobwebs. Neuron (2001) 2.87
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron (2006) 2.76
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 2.66
Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron (2004) 2.65
Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta (2000) 2.46
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 2.44
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Insulin increases CSF Abeta42 levels in normal older adults. Neurology (2003) 2.27
Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol (1998) 2.25
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature (1989) 2.04
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol (2003) 1.98
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol (1999) 1.96
Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci (2001) 1.95
Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. Neurosci Lett (1989) 1.91
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci (2003) 1.88
Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology (2007) 1.88
Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev (2000) 1.85
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol (2007) 1.81
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem (1996) 1.61
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun (2000) 1.57
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 1.51
Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging (1996) 1.49
Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem (2007) 1.46
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology (2007) 1.45
Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol (2005) 1.45
Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology (2003) 1.44
Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett (2001) 1.44
Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem (2007) 1.43
Alzheimer vaccine: amyloid-beta on trial. Bioessays (2003) 1.43
Structural and functional aspects of the blood-brain barrier. Prog Drug Res (2003) 1.42
Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem (1997) 1.40
The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem (1990) 1.36
Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem (1997) 1.35
Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol (2005) 1.33
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res (2006) 1.28
Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J Neurosci (2006) 1.24
High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (1999) 1.23
Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2006) 1.23
Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology (2004) 1.23
Biomarkers for Alzheimer's disease--clinical needs and application. J Alzheimers Dis (2005) 1.21
Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun (1995) 1.19
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol (2006) 2.68
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging (2004) 2.31
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A (2010) 1.81
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol (2005) 1.74
Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery. Ann Thorac Surg (2006) 1.64
Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet (2007) 1.56
Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell (2011) 1.52
Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.49
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging (2004) 1.44
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol (2011) 1.40
Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging (2002) 1.36
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging (2007) 1.34
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci (2004) 1.31
NDRG2: a novel Alzheimer's disease associated protein. Neurobiol Dis (2004) 1.29
S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A (2009) 1.20
Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol (2013) 1.19
Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol (2008) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging (2010) 1.16
Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis (2009) 1.15
Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener (2013) 1.13
Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum Mol Genet (2010) 1.12
MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet (2012) 1.11
PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet (2011) 1.11
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol (2012) 1.09
Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology (2011) 1.02
Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol (2013) 0.99
Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol (2003) 0.98
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J Clin Invest (2014) 0.96
Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model. J Neurosci (2013) 0.96
Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano (2014) 0.96
Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging (2010) 0.96
Personality and resilience to Alzheimer's disease neuropathology: a prospective autopsy study. Neurobiol Aging (2012) 0.95
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease. J Neurochem (2013) 0.94
Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. Mol Cell Endocrinol (2006) 0.93
Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis (2004) 0.92
Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol (2003) 0.92
Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol (2003) 0.91
Noninvasive assessment of brain injury in a canine model of hypothermic circulatory arrest using magnetic resonance spectroscopy. Ann Thorac Surg (2006) 0.90
Alpha II-spectrin breakdown products serve as novel markers of brain injury severity in a canine model of hypothermic circulatory arrest. Ann Thorac Surg (2009) 0.90
Conformational specificity of the C4F6 SOD1 antibody; low frequency of reactivity in sporadic ALS cases. Acta Neuropathol Commun (2014) 0.89
Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord (2012) 0.89
Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol (2003) 0.88
Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem (2011) 0.88
Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease. Subst Use Misuse (2010) 0.88
Amyloid precursor protein increases cortical neuron size in transgenic mice. Neurobiol Aging (2008) 0.88
Early involvement of small inhibitory cortical interneurons in Alzheimer's disease. Acta Neuropathol (2006) 0.86
The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun (2014) 0.85
Glutamate excitotoxicity mediates neuronal apoptosis after hypothermic circulatory arrest. Ann Thorac Surg (2010) 0.85
The prevalence of Alzheimer neuropathologic lesions is similar in blacks and whites. J Neuropathol Exp Neurol (2006) 0.85
Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol (2008) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age. Cogn Behav Neurol (2015) 0.83
Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest. J Thorac Cardiovasc Surg (2011) 0.83
Brain injury in canine models of cardiac surgery. J Neuropathol Exp Neurol (2014) 0.82
Hawley H. Seiler Resident Award. Transcriptional profile of brain injury in hypothermic circulatory arrest and cardiopulmonary bypass. Ann Thorac Surg (2010) 0.82
Accidental intrathecal administration of vincristine. Am J Forensic Med Pathol (2010) 0.81
Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci (2004) 0.81
Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol (2014) 0.80
Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest (2016) 0.80
Longitudinal brain activity changes in asymptomatic Alzheimer disease. Brain Behav (2012) 0.80
Pseudolaminar necrosis in cyanide intoxication: a neuropathology case report. Am J Forensic Med Pathol (2005) 0.80
U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener (2014) 0.80
C9orf72 Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. Neurodegener Dis (2016) 0.79
Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes. J Neuropathol Exp Neurol (2013) 0.79
Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation. Brain Pathol (2013) 0.78
Rates of depression in individuals with pathologic but not clinical Alzheimer disease are lower than those in individuals without the disease: findings from the Baltimore Longitudinal Study on Aging (BLSA). Alzheimer Dis Assoc Disord (2007) 0.78
Passive (amyloid-β) immunotherapy attenuates monoaminergic axonal degeneration in the AβPPswe/PS1dE9 mice. J Alzheimers Dis (2011) 0.78
Causes of unexpected death in patients with multiple sclerosis: a forensic study of 50 cases. Am J Forensic Med Pathol (2005) 0.77
In vitro assembly properties of mutant and chimeric intermediate filament proteins: insight into the function of sequences in the rod and end domains of IF. Exp Cell Res (2004) 0.77